Leishmaniasis: current status of available drugs and new potential drug targets
The control of Leishmania infection relies primarily on chemotherapy till date. Resistance to
pentavalent antimonials, which have been the recommended drugs to treat cutaneous and …
pentavalent antimonials, which have been the recommended drugs to treat cutaneous and …
Natural product based leads to fight against leishmaniasis
The growing incidence of parasitic resistance against generic pentavalent antimonials,
specifically for visceral disease in Indian subcontinent, is a serious issue in Leishmania …
specifically for visceral disease in Indian subcontinent, is a serious issue in Leishmania …
Antileishmanial drug discovery: Comprehensive review of the last 10 years
Leishmaniasis, a group of diseases caused by hemoflagellate obligate intracellular protozoa
(trypanosomatids) from the genus Leishmania, has not received the attention it deserves …
(trypanosomatids) from the genus Leishmania, has not received the attention it deserves …
[HTML][HTML] The leishmanicidal flavonols quercetin and quercitrin target Leishmania (Leishmania) amazonensis arginase
ER da Silva, C do Carmo Maquiaveli… - Experimental …, 2012 - Elsevier
Polyamine biosynthesis enzymes are promising drug targets for the treatment of
leishmaniasis, Chagas' disease and African sleeping sickness. Arginase, which is a …
leishmaniasis, Chagas' disease and African sleeping sickness. Arginase, which is a …
Polyamine metabolism in Leishmania: from arginine to trypanothione
Polyamines (PAs) are essential metabolites in eukaryotes, participating in a variety of
proliferative processes, and in trypanosomatid protozoa play an additional role in the …
proliferative processes, and in trypanosomatid protozoa play an additional role in the …
Emerging therapeutic targets for treatment of leishmaniasis
S Sundar, B Singh - Expert opinion on therapeutic targets, 2018 - Taylor & Francis
Introduction: Parasitic diseases that pose a threat to human life include leishmaniasis–
caused by protozoan parasite Leishmania species. Existing drugs have limitations due to …
caused by protozoan parasite Leishmania species. Existing drugs have limitations due to …
Induction of mitochondrial dysfunction and oxidative stress in Leishmania donovani by orally active clerodane diterpene
M Kathuria, A Bhattacharjee… - Antimicrobial agents …, 2014 - Am Soc Microbiol
This study was performed to investigate the mechanistic aspects of cell death induced by a
clerodane diterpene (K-09) in Leishmania donovani promastigotes that was previously …
clerodane diterpene (K-09) in Leishmania donovani promastigotes that was previously …
The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug …
J Almeida-Silva, DS Menezes… - Frontiers in Cellular …, 2022 - frontiersin.org
Chagas disease (CD) affects at least 6 million people in 21 South American countries
besides several thousand in other nations all over the world. It is estimated that at least …
besides several thousand in other nations all over the world. It is estimated that at least …
[HTML][HTML] The effects on Trypanosoma cruzi of novel synthetic naphthoquinones are mediated by mitochondrial dysfunction
Despite ongoing efforts, the current treatment for Chagas disease is still unsatisfactory,
mainly because of the severe side effects and variable efficacy of the available …
mainly because of the severe side effects and variable efficacy of the available …
Polyamine homoeostasis as a drug target in pathogenic protozoa: peculiarities and possibilities
LM Birkholtz, M Williams, J Niemand… - Biochemical …, 2011 - portlandpress.com
New drugs are urgently needed for the treatment of tropical and subtropical parasitic
diseases, such as African sleeping sickness, Chagas' disease, leishmaniasis and malaria …
diseases, such as African sleeping sickness, Chagas' disease, leishmaniasis and malaria …